CTOs on the Move


 
electroCore is, a US based electroceutical healthcare company, which is developing a range of non-invasive Vagus Nerve Stimulation (nVNS) patient administered therapies for the treatment of multiple conditions in neurology, psychiatry, gastroenterology and other fields. Initial focus is on primary headache (migraine and cluster headache), with trials continuing in epilepsy, gastric motility disorders, depression and anxiety. electroCore, which was founded in 2005, has more than 30 employees and full time consultants with offices in the US (head office), Germany (German and European head office), UK, Italy, Australia, and Canada.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

ElectroCore raised $36M on 09/10/2017
ElectroCore raised $34M on 11/29/2017

Similar Companies

Cecelia Health

Cecelia Health partners with health plans/providers seeking to improve quality measures, and pharmaceutical/medical device companies seeking to improve adherence.

University of Pittsburgh Center for BioSecurity

University of Pittsburgh Center for BioSecurity is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Refeyn

Refeyn is a company that specializes in label-free single molecule imaging and mass measurement of biomolecules in solution using mass photometry technology.

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.

Apos Therapy

AposTherapy provides a clinically proven, innovative, drug-free, at-home treatment for reducing pain and improving function in patients suffering from knee osteoarthritis and chronic lower back or hip pain.